Drug
Omalizumab clinical trials
Also written Xolair, IGE025 and CT-P39.
- studies test it
- 165
- open now
- 10
- in phase 3
- 42
- first study started
- 2000
Keep track of what changes. Save the Omalizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Xolair
- 82
Studies by the year they started
164 studies that test it; most in 2009 (13)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 3 |
| 2003 | 5 |
| 2004 | 9 |
| 2005 | 11 |
| 2006 | 12 |
| 2007 | 9 |
| 2008 | 3 |
| 2009 | 13 |
| 2010 | 6 |
| 2011 | 7 |
| 2012 | 6 |
| 2013 | 8 |
| 2014 | 11 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 9 |
| 2018 | 4 |
| 2019 | 6 |
| 2020 | 7 |
| 2021 | 8 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 17
- Phase 2
- 47
- Phase 3
- 42
- Phase 4
- 54
- No phase
- 10
What it is tested for
Each study’s main condition, where its own words name it.
- Asthma
- 56
Who runs them
Industry 63 · Other 102
Novartis Pharmaceuticals (19) · Genentech, Inc. (16) · Johns Hopkins University (11) · Novartis (11) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Stanford University (5) · Hoffmann-La Roche (4) · Creighton University (4)
Often tested with
Tested in the same studies.
Dupilumab (2) · Mepolizumab (2) · TEV-45779 (1) · cow's milk (1) · Peanut (1) · Fluticasone (1) · Remibrutinib (1) · EXL-111 (1)
Studies
Open first, then newest update. How each study uses Omalizumab is read from its arms, and is right about nine times in ten.
Testing it · 165
- Oral Food Challenge After One to Two Doses of Omalizumab Treatment for Food AllergyNot yet recruitingPhase 4Johns Hopkins UniversityNCT07845552Written as Omalizumab
- Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 WeeksRecruitingPhase 3Novartis PharmaceuticalsNCT07816328Written as Omalizumab
- A Study to Find a Suitable Dose of Exl-111 for Further ResearchRecruitingPhase 1Excellergy Inc.NCT07356713Written as Omalizumab
- Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPDRecruitingPhase 2Johns Hopkins UniversityNCT07059091Written as Omalizumab (Xolair®)
- Omalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE LevelsRecruitingPhase 2Johns Hopkins UniversityNCT06934200Written as Omalizumab
- Omalizumab Weight-Based Dosing Efficacy TrialRecruitingPhase 2Massachusetts General HospitalNCT06943534Written as 5mg/kg omalizumab injection
- Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous UrticariaRecruitingPhase 4Simon Francis ThomsenNCT05916937Written as omalizumab 300 mg every four weeks
- Omalizumab Before Onset of ExacerbationsRecruitingPhase 2Children's National Research InstituteNCT05332067Written as Omalizumab
- Effect of Omalizumab in the Skin of Food Allergy PatientsRecruitingPhase 4National Jewish HealthNCT06618963Written as Omalizumab Injection
- Biologics and Sublingual ImmunotherapyNot yet recruitingPhase 4Medical University of SilesiaNCT06027073Written as omalizumab
- Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic ParticipantsCompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT03881696Written as Omalizumab
- A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788gCompletedPhase 2Genentech, Inc.NCT00382148Written as omalizumab
- Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)CompletedPhase 2Stanford UniversityNCT03679676Written as Omalizumab
- Multi OIT to Test Immune Markers After Minimum Maintenance DoseCompletedPhase 2Andrew Long, PharmDNCT03181009Written as Omalizumab
- Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent PatientsCompletedPhase 3Novartis PharmaceuticalsNCT03369704Written as Omalizumab
- Preventing Asthma in High Risk KidsActive, not recruitingPhase 2Boston Children's HospitalNCT02570984Written as Omalizumab
- EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 PatientsCompletedPhase 4SanofiNCT04998604Written as Omalizumab
- Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic UrticariaCompletedPhase 3Teva Pharmaceuticals USANCT04976192Written as XOLAIR® Injection
- FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FAActive, not recruitingPhase 4AAADRS Clinical Research CenterNCT06437171Written as Omalizumab
- To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous UrticariaCompletedPhase 3CelltrionNCT04426890Written as CT-P39
See all 165 studies that test Omalizumab →
Given in every arm · 2 — Omalizumab is usual care beside what is tested
- E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food AllergyStatus unknownPhase 2Xiu-Min LiNCT02879006Written as Omalizumab
- Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab DiscontinuationWithdrawnPhase 4Selina Gierer, D.O.NCT02742805Written as Omalizumab
As the comparator · 22 — what is tested is compared with Omalizumab
- Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma PatientsRecruitingPhase 2Longbio PharmaNCT07342803Written as Omalizumab
- Trial of JYB1904 in Chronic Spontaneous Urticaria.RecruitingPhase 2JemincareNCT06509334Written as Omalizumab
- Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) TreatmentCompletedPhase 2Longbio PharmaNCT06228560Written as Omalizumab
- Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.Active, not recruitingPhase 3Novartis PharmaceuticalsNCT06042478Written as Omalizumab
- To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous UrticariaCompletedPhase 3Taizhou Mabtech Pharmaceutical Co.,LtdNCT06365879Written as Xolair
- Trial of JYB1904 in Patients With Allergic AsthmaCompletedPhase 2JemincareNCT06438757Written as Omalizumab
- Compare the PK, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in Healthy Adult Male SubjectsCompletedPhase 1Taizhou Mabtech Pharmaceutical Co.,LtdNCT07246252Written as Xolair (omalizumab)
- Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single InjectionTerminatedPhase 1BioRay Pharmaceutical Co., Ltd.NCT04361812Written as Omalizumab (Xolair®)
- Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous UrticariaCompletedPhase 2AmgenNCT04833855Written as Omalizumab
- A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic DiseasesCompletedPhase 1Yuhan CorporationNCT05564221Written as Omalizumab
- A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.CompletedPhase 3Novartis PharmaceuticalsNCT03580356Written as Omalizumab
- A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects with Mild Allergic DiseasesCompletedPhase 1Yuhan CorporationNCT05061524Written as Omalizumab
- A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic DiseasesCompletedPhase 1Yuhan CorporationNCT05960708Written as Omalizumab
- A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistaminesCompletedPhase 3Novartis PharmaceuticalsNCT03580369Written as Omalizumab
- Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese SubjectsCompletedPhase 1JemincareNCT05449535Written as Omalizumab
- The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD, Safety and ImmunogenicityCompletedPhase 1Taizhou Mabtech Pharmaceutical Co.,LtdNCT05897008Written as Xolair
- Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSUCompletedPhase 2Novartis PharmaceuticalsNCT02477332Written as Omalizumab
- An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial AsthmaCompletedPhase 3AO GENERIUMNCT04607629Written as Xolair® + Symbicort®
- Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With AsthmaCompletedPhase 2Novartis PharmaceuticalsNCT01716754Written as Omalizumab
- A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic AsthmaCompletedPhase 1/2Novartis PharmaceuticalsNCT01703312Written as omalizumab
Showing 20 of 22.
Codes
What other systems call Omalizumab · ClinicalTrials.gg INT006578
- MeSH (NLM) D000069444OmalizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 2P471X1Z11OMALIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 302379Confirmed FDA, Wikidata
- Wikidata Q415392omalizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C29299OmalizumabOne source FDA
- DrugBank DB00043One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069444 | Omalizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 2P471X1Z11 | OMALIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 302379 | — | Confirmed FDA, Wikidata |
| Wikidata | Q415392 | omalizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C29299 | Omalizumab | One source FDA |
| DrugBank | DB00043 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.